WO2000004014A1 - Derives de pyrimidine manifestant une activite antitumorale - Google Patents
Derives de pyrimidine manifestant une activite antitumorale Download PDFInfo
- Publication number
- WO2000004014A1 WO2000004014A1 PCT/JP1999/003863 JP9903863W WO0004014A1 WO 2000004014 A1 WO2000004014 A1 WO 2000004014A1 JP 9903863 W JP9903863 W JP 9903863W WO 0004014 A1 WO0004014 A1 WO 0004014A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antitumor activity
- pyrimidine derivatives
- derivatives exhibiting
- exhibiting antitumor
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002336832A CA2336832A1 (en) | 1998-07-16 | 1999-07-16 | Pyrimidine derivatives exhibiting antitumor activity |
US09/743,721 US6420367B1 (en) | 1998-07-16 | 1999-07-16 | Pyrimidine derivatives exhibiting antitumor activity |
KR1020017000686A KR20010071936A (ko) | 1998-07-16 | 1999-07-16 | 항종양 활성을 갖는 피리미딘 유도체 |
EP99929886A EP1097933A4 (en) | 1998-07-16 | 1999-07-16 | PYRIMIDINE DERIVATIVES HAVING ANTI-TUMOR ACTIVITY |
JP2000560120A JP3910365B2 (ja) | 1998-07-16 | 1999-07-16 | 抗腫瘍活性を有するピリミジン誘導体 |
AU46540/99A AU748816B2 (en) | 1998-07-16 | 1999-07-16 | Pyrimidine derivatives exhibiting antitumor activity |
HK02101842.6A HK1040400A1 (zh) | 1998-07-16 | 2002-03-11 | 具有抗腫瘤活性的嘧啶衍生物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/201423 | 1998-07-16 | ||
JP20142398 | 1998-07-16 | ||
JP11032099 | 1999-04-19 | ||
JP11/110320 | 1999-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000004014A1 true WO2000004014A1 (fr) | 2000-01-27 |
Family
ID=26449971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/003863 WO2000004014A1 (fr) | 1998-07-16 | 1999-07-16 | Derives de pyrimidine manifestant une activite antitumorale |
Country Status (10)
Country | Link |
---|---|
US (1) | US6420367B1 (ja) |
EP (1) | EP1097933A4 (ja) |
JP (1) | JP3910365B2 (ja) |
KR (1) | KR20010071936A (ja) |
CN (1) | CN1146561C (ja) |
AU (1) | AU748816B2 (ja) |
CA (1) | CA2336832A1 (ja) |
HK (1) | HK1040400A1 (ja) |
TW (1) | TW548275B (ja) |
WO (1) | WO2000004014A1 (ja) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051488A1 (fr) * | 2000-01-14 | 2001-07-19 | Shionogi & Co., Ltd. | Derives de la pyrimidine a effet anti-tumoral |
WO2008016123A1 (fr) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
US8410112B2 (en) | 2008-11-10 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841308B2 (en) | 2008-12-19 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazin-2-amines useful as inhibitors of ATR kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8877759B2 (en) | 2011-04-05 | 2014-11-04 | Vertex Pharnaceuticals Incorporated | Aminopyrazines as ATR kinase inhibitors |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
CN104592217B (zh) * | 2014-12-09 | 2018-03-13 | 沈阳药科大学 | 3‑(1,3,4‑噁二唑基)‑5‑苯氧基‑吡啶类衍生物及其制备方法与应用 |
EP3693369A3 (en) | 2016-04-15 | 2020-09-09 | AbbVie Inc. | Bromodomain inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08504215A (ja) * | 1993-10-01 | 1996-05-07 | チバ−ガイギー アクチェンゲゼルシャフト | 薬理学的に活性なピリジン誘導体及びその製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6157587A (ja) * | 1984-08-29 | 1986-03-24 | Shionogi & Co Ltd | 縮合複素環誘導体および抗潰瘍剤 |
-
1999
- 1999-07-16 US US09/743,721 patent/US6420367B1/en not_active Expired - Fee Related
- 1999-07-16 CA CA002336832A patent/CA2336832A1/en not_active Abandoned
- 1999-07-16 KR KR1020017000686A patent/KR20010071936A/ko active IP Right Grant
- 1999-07-16 AU AU46540/99A patent/AU748816B2/en not_active Ceased
- 1999-07-16 WO PCT/JP1999/003863 patent/WO2000004014A1/ja not_active Application Discontinuation
- 1999-07-16 CN CNB998108057A patent/CN1146561C/zh not_active Expired - Fee Related
- 1999-07-16 EP EP99929886A patent/EP1097933A4/en not_active Withdrawn
- 1999-07-16 JP JP2000560120A patent/JP3910365B2/ja not_active Expired - Fee Related
- 1999-07-16 TW TW088112093A patent/TW548275B/zh not_active IP Right Cessation
-
2002
- 2002-03-11 HK HK02101842.6A patent/HK1040400A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08504215A (ja) * | 1993-10-01 | 1996-05-07 | チバ−ガイギー アクチェンゲゼルシャフト | 薬理学的に活性なピリジン誘導体及びその製造方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1097933A4 * |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051488A1 (fr) * | 2000-01-14 | 2001-07-19 | Shionogi & Co., Ltd. | Derives de la pyrimidine a effet anti-tumoral |
US6800630B2 (en) | 2000-01-14 | 2004-10-05 | Shionogi & Co., Ltd. | Pyrimidine derivatives having antitumor effect |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
WO2008016123A1 (fr) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
US8410112B2 (en) | 2008-11-10 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9365557B2 (en) | 2008-12-19 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US9701674B2 (en) | 2008-12-19 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US10961232B2 (en) | 2008-12-19 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US8841308B2 (en) | 2008-12-19 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazin-2-amines useful as inhibitors of ATR kinase |
US10479784B2 (en) | 2008-12-19 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8877759B2 (en) | 2011-04-05 | 2014-11-04 | Vertex Pharnaceuticals Incorporated | Aminopyrazines as ATR kinase inhibitors |
US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10208027B2 (en) | 2011-09-30 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9862709B2 (en) | 2011-09-30 | 2018-01-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US10822331B2 (en) | 2011-09-30 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11110086B2 (en) | 2012-04-05 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10787452B2 (en) | 2012-12-07 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11370798B2 (en) | 2012-12-07 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11117900B2 (en) | 2012-12-07 | 2021-09-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10392391B2 (en) | 2012-12-07 | 2019-08-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9650381B2 (en) | 2012-12-07 | 2017-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9718827B2 (en) | 2012-12-07 | 2017-08-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10815239B2 (en) | 2013-12-06 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11485739B2 (en) | 2013-12-06 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10800781B2 (en) | 2014-06-05 | 2020-10-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10093676B2 (en) | 2014-06-05 | 2018-10-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Also Published As
Publication number | Publication date |
---|---|
HK1040400A1 (zh) | 2002-06-07 |
CN1146561C (zh) | 2004-04-21 |
AU748816B2 (en) | 2002-06-13 |
TW548275B (en) | 2003-08-21 |
US6420367B1 (en) | 2002-07-16 |
AU4654099A (en) | 2000-02-07 |
CN1317003A (zh) | 2001-10-10 |
JP3910365B2 (ja) | 2007-04-25 |
KR20010071936A (ko) | 2001-07-31 |
EP1097933A1 (en) | 2001-05-09 |
CA2336832A1 (en) | 2000-01-27 |
EP1097933A4 (en) | 2001-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000004014A1 (fr) | Derives de pyrimidine manifestant une activite antitumorale | |
EP0758653A4 (en) | IMIDAZOQUINAZOLINE DERIVATIVES | |
CA2165819A1 (en) | Dc-89 derivatives | |
EP1085021A4 (en) | DERIVATIVES OF PYRROLO 1,2-B] PYRIDAZINE, WITH INHIBITOR EFFECT ON SPLA 2? | |
KR100188846B1 (en) | Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives | |
BG100656A (en) | Derivatives of naphthalene, method and intermediate compounds for their preparation | |
EP0978516A4 (en) | 1-CYCLOALKYL-1,8-NAPHTHYRIDINE-4-ONE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITING ACTIVITY | |
CA2396738A1 (en) | Thiazole derivatives as active superoxide radical inhibitors | |
EP1069110A4 (en) | SULFONAMIDE DERIVATIVES | |
AU2799392A (en) | Piperazic acid derivatives as collagenase inhibitor | |
CA2226894A1 (en) | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | |
AU9281198A (en) | Benzofuran derivatives | |
EP1201668A4 (en) | STAUROSPORINE DERIVATIVES | |
MY117092A (en) | Chemotherapeutic pyrrolocarbazole derivatives | |
EP1454903A4 (en) | THIADIAZOLINDERIVAT | |
CA2152817A1 (en) | Novel Pyridone Carboxylic Acid Derivatives | |
ES2093091T3 (es) | Derivado de glutation. | |
CA2209422A1 (en) | 4-amino-3-acylnaphthyridine derivatives | |
EP1020459A4 (en) | CIS DISUBSTITUTED AMINOCYCLOALKYL PYRROLIDINE DERIVATIVES | |
EP1099690A4 (en) | MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM | |
EP1074545A4 (en) | ISOCHINOLINE SULPHONAMIDE DERIVATIVES AND MEDICINES CONTAINING IT AS AN ACTIVE INGREDIENT | |
EP1264829A4 (en) | OXYGEN-CONTAINING HETEROCYCLES | |
EP0782988A4 (en) | INDOL DERIVATIVES | |
RS50449B (sr) | Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija | |
AU2001225466A1 (en) | Pyrimidine derivatives having antitumor effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810805.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 46540/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2336832 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00283 Country of ref document: ZA Ref document number: 200100283 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743721 Country of ref document: US Ref document number: 1020017000686 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999929886 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999929886 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 46540/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999929886 Country of ref document: EP |